how do glp-1 agonists work Frontiers GLP-1 & GIP Agonists |

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Curious about GLP-1 medications like Ozempic and Wegovy

Discover how this sugar may boost GLP-1, reduce body fat, and support long-term metabolic health.

#GLP1 #DiabetesCare #ObesityManagement #PharmaIndustry #ClinicalResearch #DrugDevelopment #HealthcareInnovation #Endocrinology #Biotech #RegulatoryAffairs

Developing drugs for metabolic dysfunction-associated steatohepatitis (MASH) has been a surprisingly challenging task

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes